BNTX Stock Price Today: Pfizer-BioNTech prepare for Emergency Use Authorization from the FDA on Thursday
Premium|Take advantage of 75% OFF on your first month.
Grab this special offer, it's a 1 year for FREE deal! And access ALL our articles and analysis.
You have reached your limit of 5 free articles for this month.
BLACK FRIDAY SALE! 75% OFF!
Grab this special offer, it's a 1 year for FREE deal! And access ALL our articles and analysis.
CLAIM OFFER- NASDAQ:BNTX falls during the trading session but rebounds after hours.
- Canada is the most recent country to authorize the Pfizer-BioNTech vaccine for use.
- Pfizer and BioNTech pulled back after reported allergic reactions after receiving the vaccine in the UK.
NASDAQ:BNTX did not have the day it was expected to on the eve of the FDA approving one of the most important vaccines of our lifetimes. The stock retreated by 4.14% on Wednesday, amidst a myriad of causes including a global market selloff as well as reported adverse reactions to its vaccine. Shares are still just below all-time highs and have a chance to rebound tomorrow if all goes smoothly with the FDA.
BioNTech and Pfizer (NYSE:PFE) fell on Wednesday, a day after the first doses of the vaccine were delivered to people in the United Kingdom. Some people reported allergic reactions and although most medical professionals are downplaying this as a typical reaction to any vaccine, investors were not as easily convinced. The two biotech companies did mention that the vaccine may have some adverse effects on people with a history of serious allergies, or people who have reacted to vaccines in the past. Most allergic reactions are said to occur from the non-medicinal parts of the vaccine, so much of this was expected by health officials around the world.
BNTX stock forecast
Health Canada became the latest country to authorize BioNTech and Pfizer’s vaccine on Wednesday but did mention they are monitoring the allergic reaction news closely. Canada has also ordered vaccines from Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) so if more complications arise with BioNTech’s vaccine, there are plenty of other companies that are willing to step up. Investors await the news tomorrow from the FDA although all indications are that the vaccine will be approved without a hitch.
- NASDAQ:BNTX falls during the trading session but rebounds after hours.
- Canada is the most recent country to authorize the Pfizer-BioNTech vaccine for use.
- Pfizer and BioNTech pulled back after reported allergic reactions after receiving the vaccine in the UK.
NASDAQ:BNTX did not have the day it was expected to on the eve of the FDA approving one of the most important vaccines of our lifetimes. The stock retreated by 4.14% on Wednesday, amidst a myriad of causes including a global market selloff as well as reported adverse reactions to its vaccine. Shares are still just below all-time highs and have a chance to rebound tomorrow if all goes smoothly with the FDA.
BioNTech and Pfizer (NYSE:PFE) fell on Wednesday, a day after the first doses of the vaccine were delivered to people in the United Kingdom. Some people reported allergic reactions and although most medical professionals are downplaying this as a typical reaction to any vaccine, investors were not as easily convinced. The two biotech companies did mention that the vaccine may have some adverse effects on people with a history of serious allergies, or people who have reacted to vaccines in the past. Most allergic reactions are said to occur from the non-medicinal parts of the vaccine, so much of this was expected by health officials around the world.
BNTX stock forecast
Health Canada became the latest country to authorize BioNTech and Pfizer’s vaccine on Wednesday but did mention they are monitoring the allergic reaction news closely. Canada has also ordered vaccines from Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) so if more complications arise with BioNTech’s vaccine, there are plenty of other companies that are willing to step up. Investors await the news tomorrow from the FDA although all indications are that the vaccine will be approved without a hitch.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.